Author: healthprofessionalradio

Scott Megaffin, CEO of Adastra Pharmaceuticals, Inc., a company focused on the treatment of cancers with high unmet needs (such as high-grade gliomas), discusses positive top-line data from their Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib (ZTR/TG02) in combination with temozolomide (TMZ) in patients with recurrent high-grade gliomas, which have a near-100% mortality rate and very limited therapeutic options.  He also talks about Adastra’s plans for the future development of ZTR.

Astellas Oncology has announced the three finalists for the 2020 C3 Prize (Changing Cancer Care).  One of the finalists, Lisa McKenzie is here to share her vision in Changing Cancer Care with “You Night Empowering Events: A narrative therapy storytelling course that helps cancer patients articulate their life’s journey, find their inner strength, and encourage others with cancer”.  The finalists will pitch their ideas to an expert judging panel of leaders in business, innovation, and cancer care, with cancer activist and entrepreneur Bill Rancic serving as emcee, at a virtual pitch event on March 23, 2021.

Marc Meachem, Head of External Affairs U.S. at ViiV Healthcare, discusses a recent report released by ViiV Healthcare called “Tal Como Soy/Here as I Am” which analyzed multiple factors that contribute to the disproportionate impact on Latinx LGBTQ+ men’s ability to access preventive care and HIV treatment.  He talks about how this report and learned insights can help healthcare professionals improve care and access. 

Returning guest and study author, Steve Shak, Chief Medical Officer at Exact Sciences discusses results presented at SABCS (San Antonio Breast Cancer Symposium) from the Phase 3 RxPONDER (Rx for Positive Node, Endocrine Responsive) study, one of the largest randomized, prospective clinical trials in women with node-positive, hormone receptor-positive (HR+), HER2- early-stage breast cancer.

John Huemoeller, CEO of AXIM Biotechnologies, an international healthcare solutions company based in San Diego targeting oncological and COVID-19 research, discusses three first-of-their-kind COVID-19 neutralizing antibody tests. They have developed the world’s first rapid diagnostic test for detecting COVID-19 neutralizing antibodies and are waiting on EUA approval based on its proven test’s accuracy in blood and serum.

Dave Marver, CEO of ONWARD, discusses the work they are doing with both non-invasive and implantable neuromodulation technologies to improve the quality of life for people with spinal cord injury. The company just enrolled the first patient in its clinical trial, Up-LIFT, which is testing the safety and effectiveness of ARC Therapy™ in restoring hand and arm function in people living with spinal cord injury.

Paul Brennan, President and CEO of NervGen Pharma Corp, developer of treatments related to nerve damage and neurodegenerative diseases, discusses the struggle for financial backing for the development of drugs to treat conditions such as traumatic brain injury and stroke. He compares this to the ‘money’ available to finding an effective treatment and cure for Alzheimer’s disease.

Steven Engle, CEO of CohBar, Inc, a clinical stage biotechnology company discusses his article in “Grit Daily” (Jan 8, 2021) on NASA’s breakthrough study published in “Cell” (Nov 25, 2020) on the effects of space travel on mitochondria.

Dr. Mike, a clinical psychologist discusses the podcast he is hosting called “Going There“. presented by Sound Mind Live and Consequences of Sound.  The weekly podcast aims to create a safe space for musicians to have honest, healthy conversations about mental health. Each episode covers the experience of artists and creatives as it pertains to specific issues, be it depression, anxiety, addiction, whatever they bring to the table. The goal is to de-stigmatize these topics and learn from each other.

Dr. Tania Gonzalez-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK) discusses the recent FDA approval of BENLYSTA (Belimumab) the first and only approved biologic treatment for both lupus and adult patients with active lupus nephritis who are receiving standard therapy. This approval builds on 10 years of clinical evidence.